The decision was made because Astellas found it was difficult to find a partner for the Phase III clinical development and commercialization of darexaban.
The company also considered that this product has intensified competition and the order of priority in its pipeline.
Astellas’ darexaban maleate was developed to prevent indications of ischemic events in acute coronary syndrome, stroke prevention in atrial fibrillation and venous thromboembolism after major orthopedic surgery.